Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GOVX - GeoVax Labs, Inc.

IEX Last Trade
2.44
0.020   0.820%

Share volume: 3,859
Last Updated: Fri 27 Dec 2024 08:29:46 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$2.42
0.02
0.83%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
6.33%
1 Month
-13.28%
3 Months
-4.08%
6 Months
-26.33%
1 Year
-58.00%
2 Year
326.03%
Key data
Stock price
$2.44
P/E Ratio 
0.00
DAY RANGE
$2.36 - $2.50
EPS 
$0.00
52 WEEK RANGE
$0.38 - $11.18
52 WEEK CHANGE
-$56.60
MARKET CAP 
24.371 M
YIELD 
N/A
SHARES OUTSTANDING 
5.264 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$741,702
AVERAGE 30 VOLUME 
$646,063
Company detail
CEO: David A. Dodd
Region: US
Website: geovax.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

GeoVax Labs, Inc. develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV) and malaria.

Recent news